No one wants to run this company, its to far gone
Post# of 11802
Keith Berman, CEO of Decision Diagnostics commented, "On September 1, 2017 the Board of Directors received a revised confidential cash offer from our previously disclosed M&A partner. The revised offer is again substantially above our current stock price highlighting the faith and confidence our hopeful future partners have in our past successes and our projected sales on the two new products, GenSure! and GenChoice! and our current mainstay, the GenUltimate!."
Mr. Berman continued, "This new offer represents a 21% improvement over the proposals previously disclosed in July 2017, again highlighting the enthusiasm of the M&A candidate to become partnered us. Those who know DECN, know that we are extreme at vetting our partners and lenders and turn down many more offers than we have accepted, and it continues to work for us. The Board cautions shareholders to be patient and allow this process to come to its natural conclusion."